𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of growth and radiation response of KHT tumor cells metastatic from lung to ovary and kidney

✍ Scribed by Dietmar W. Siemann; R. Timothy Mulcahy


Book ID
104634561
Publisher
Springer
Year
1984
Tongue
English
Weight
549 KB
Volume
2
Category
Article
ISSN
0262-0898

No coin nor oath required. For personal study only.

✦ Synopsis


Female C3H/HeJ mice were inoculated intravenously with KHT sarcoma cells. Once macroscopic colonies were established in the lungs, the thoraces of the animals were locally irradiated. Despite significant lung nodule regression following treatment, animals were observed to die with ovarian and renal metastases. By irradiating the lungs at various times after intravenous tumor cell injection, it was demonstrated that ovarian and renal metastases arose only from established lung colonies and were not a consequence of the initial cell inoculum. Incidence of metastases increased from 0 to 100 per cent when the time between cell inoculation and thoracic irradiation was increased from 4 to 16 days. Once established, ovarian and renal metastases grew with a doubling time of approximately 1-2 days. Metastatic tumors in the ovaries were found to be refractory to radiation therapy because of a large component of radiationresistant hypoxic cells. Parallel experiments utilizing male C3H/HeJ mice demonstrated metastases only in the kidneys and these grew at a growth rate similar to that seen for renal metastases in female mice. This system may serve as a model for the study of factors influencing the dissemination of tumor cells to these anatomical sites and their response to treatment.


πŸ“œ SIMILAR VOLUMES


Response to dual blockade of epidermal g
✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 332 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2